Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …

Purpose Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors have proven
efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib …

To demonstrate that a biomarker is predictive of treatment benefit, the study requires
biomarker status on all patients as well as patients who were treated with the agent of …

Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …

Background In cancer therapy, molecularly targeted agents have the potential to maximize
antitumor efficacy while minimizing treatment-related toxicity. However, these agents may …

The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over
chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell …

Purpose To describe the emergence of targeted therapies that have led to significant
breakthroughs in cancer therapy and completed or ongoing clinical trials of novel agents for …

Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line
treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large …

Lung cancer is the leading cause of cancer mortality in the United States and worldwide.
Previously, lung cancer was simplistically divided into non–small-cell lung cancer (NSCLC) …